Global obesity-drug sales could exceed $130–150B by the mid-2030s, driven by GLP-1/GIP drugs and expanding access beyond the ...

Eli Lilly (LLY) reached $1 at the closing of the latest trading day, reflecting a +1.8% change compared to its last close.

In a significant move to address supply constraints, Eli Lilly announced a $6 billion investment to construct a new manufacturing facility in Huntsville, Alabama. This site is slated to produce both ...

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include ...

In the latest close session, Eli Lilly (LLY) was up +2.44% at $839.87. The stock exceeded the S&P 500, which registered a gain of 0.01% for the day. Elsewhere, the Dow gained 0.51%, while the ...

Eli Lilly (LLY) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...

Financial giants have made a conspicuous bullish move on Eli Lilly. Our analysis of options history for Eli Lilly (NYSE:LLY) revealed 23 unusual trades. Delving into the details, we found 47% of ...

This week, Eli Lilly secured a significant regulatory victory. The U.S. Food and Drug Administration (FDA) granted full, traditional approval for the cancer drug Jaypirca. This upgrades its status ...

Eli Lilly said on Thursday its next-generation obesity drug helped patients lose an average of 28.7% of their weight in a ...

Discover why Eli Lilly and Company's retatrutide weight loss breakthrough positions LLY as a leader in obesity therapeutics.

In November 2025, Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology firm specializing in therapies for primary ...

Pharmaceutical giant Eli Lilly has teamed up with Breakthrough Properties to build out a new incubator lab space in Center City. The 44K SF Lilly Gateway Labs at Breakthrough will feature ...